NCT01750814View on ClinicalTrials.gov

To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC3102C' Administered Intramuscularly in Healthy Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Prophylaxis Against Influenza
Interventions
BIOLOGICAL

GC3102C

a single dose (0.5 mL) intramuscularly on the deltoid muscle

BIOLOGICAL

GC FLU inj.

a single dose (0.5 mL) intramuscularly on the deltoid muscle

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY

NCT01750814 - To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC3102C' Administered Intramuscularly in Healthy Adults | Biotech Hunter | Biotech Hunter